207 related articles for article (PubMed ID: 12649104)
1. Activity of raltitrexed and gemcitabine in advanced pancreatic cancer.
Kralidis E; Aebi S; Friess H; Büchler MW; Borner MM
Ann Oncol; 2003 Apr; 14(4):574-9. PubMed ID: 12649104
[TBL] [Abstract][Full Text] [Related]
2. Raltitrexed plus gemcitabine (TOMGEM) in advanced pancreatic cancer. Results of a Belgian multicentre phase II study.
Van Laethem JL; Van Maele P; Verslype C; Polus M; Demols A; Houbiers G; Caenepeel P; Leleux A; Vermaut RR; Van Cutsem E; Peeters M
Oncology; 2004; 67(5-6):338-43. PubMed ID: 15713988
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of raltitrexed and gemcitabine in patients with advanced pancreatic carcinoma.
Arends JJ; Sleeboom HP; Leys MB; Ten Bokkel Huinink D; de Jong RS; Smit JM; Nortier JW; Tesselaar ME
Br J Cancer; 2005 Feb; 92(3):445-8. PubMed ID: 15668704
[TBL] [Abstract][Full Text] [Related]
4. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
[TBL] [Abstract][Full Text] [Related]
5. Irinotecan plus raltitrexed vs raltitrexed alone in patients with gemcitabine-pretreated advanced pancreatic adenocarcinoma.
Ulrich-Pur H; Raderer M; Verena Kornek G; Schüll B; Schmid K; Haider K; Kwasny W; Depisch D; Schneeweiss B; Lang F; Scheithauer W
Br J Cancer; 2003 Apr; 88(8):1180-4. PubMed ID: 12698181
[TBL] [Abstract][Full Text] [Related]
6. Activity of gemcitabine and continuous infusion fluorouracil in advanced pancreatic cancer.
Rauch DP; Maurer CA; Aebi S; Pampallona S; Friess H; Ludwig CU; Büchler MW; Borner MM
Oncology; 2001; 60(1):43-8. PubMed ID: 11150907
[TBL] [Abstract][Full Text] [Related]
7. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.
Hidalgo M; Castellano D; Paz-Ares L; Gravalos C; Diaz-Puente M; Hitt R; Alonso S; Cortes-Funes H
J Clin Oncol; 1999 Feb; 17(2):585-92. PubMed ID: 10080603
[TBL] [Abstract][Full Text] [Related]
8. Phase II study of gemcitabine combined with uracil-tegafur in metastatic pancreatic cancer.
Lee J; Park JO; Kim WS; Lee SI; Song SY; Lim DH; Choi SH; Heo JS; Lee KT; Lee JK; Kim K; Jung CW; Im YH; Lee MH; Kang WK; Park K
Oncology; 2004; 66(1):32-7. PubMed ID: 15031596
[TBL] [Abstract][Full Text] [Related]
9. Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma: final results of a GERCOR multicenter phase II study.
Louvet C; André T; Lledo G; Hammel P; Bleiberg H; Bouleuc C; Gamelin E; Flesch M; Cvitkovic E; de Gramont A
J Clin Oncol; 2002 Mar; 20(6):1512-8. PubMed ID: 11896099
[TBL] [Abstract][Full Text] [Related]
10. Phase II study of a fixed dose-rate infusion of gemcitabine associated with uracil/tegafur in advanced carcinoma of the pancreas.
Feliu J; Mel R; Borrega P; López Gómez L; Escudero P; Dorta J; Castro J; Vázquez-Estévez SE; Bolaños M; Espinosa E; González Barón M;
Ann Oncol; 2002 Nov; 13(11):1756-62. PubMed ID: 12419748
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of bimonthly leucovorin, 5-fluorouracil and gemcitabine for advanced pancreatic adenocarcinoma (FOLFUGEM).
Louvet C; André T; Hammel P; Selle F; Landi B; Cattan S; Fonck M; Flesch M; Colin P; Balosso J; Ruszniewski P; de Gramont A
Ann Oncol; 2001 May; 12(5):675-9. PubMed ID: 11432627
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of induction gemcitabine/CPT-11 followed by a twice-weekly infusion of gemcitabine and concurrent external beam radiation for the treatment of locally advanced pancreatic cancer.
Mishra G; Butler J; Ho C; Melin S; Case LD; Ennever PR; Magrinat GC; Bearden JD; Minotto DC; Howerton R; Levine E; Blackstock AW
Am J Clin Oncol; 2005 Aug; 28(4):345-50. PubMed ID: 16062075
[TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel plus either gemcitabine or simplified leucovorin and fluorouracil as first-line therapy for metastatic pancreatic adenocarcinoma (AFUGEM GERCOR): a non-comparative, multicentre, open-label, randomised phase 2 trial.
Bachet JB; Hammel P; Desramé J; Meurisse A; Chibaudel B; André T; Debourdeau P; Dauba J; Lecomte T; Seitz JF; Tournigand C; Aparicio T; Meyer VG; Taieb J; Volet J; Monier A; Bonnetain F; Louvet C
Lancet Gastroenterol Hepatol; 2017 May; 2(5):337-346. PubMed ID: 28397697
[TBL] [Abstract][Full Text] [Related]
14. Second-line treatment with oxaliplatin, leucovorin and 5-fluorouracil in gemcitabine-pretreated advanced pancreatic cancer: A phase II study.
Tsavaris N; Kosmas C; Skopelitis H; Gouveris P; Kopterides P; Loukeris D; Sigala F; Zorbala-Sypsa A; Felekouras E; Papalambros E
Invest New Drugs; 2005 Aug; 23(4):369-75. PubMed ID: 16012797
[TBL] [Abstract][Full Text] [Related]
15. Palliative first-line treatment with weekly high-dose 5-fluorouracil as 24h-infusion and gemcitabine in metastatic pancreatic cancer (UICC IV).
Roehrig S; Wein A; Albrecht H; Konturek PC; Reulbach U; Männlein G; Wolff K; Ostermeier N; Hohenberger W; Hahn EG; Boxberger F
Med Sci Monit; 2010 Mar; 16(3):CR124-131. PubMed ID: 20190682
[TBL] [Abstract][Full Text] [Related]
16. Fixed dose rate infusion of gemcitabine with oral doxifluridine and leucovorin for advanced unresectable pancreatic cancer: a phase II study.
Kim H; Park JH; Shin SJ; Kim MJ; Bang SJ; Park NH; Nah YW; Nam CW; Joo KR; Min YJ
Chemotherapy; 2008; 54(1):54-62. PubMed ID: 18073472
[TBL] [Abstract][Full Text] [Related]
17. Raltitrexed-eloxatin salvage chemotherapy in gemcitabine-resistant metastatic pancreatic cancer.
Reni M; Pasetto L; Aprile G; Cordio S; Bonetto E; Dell'Oro S; Passoni P; Piemonti L; Fugazza C; Luppi G; Milandri C; Nicoletti R; Zerbi A; Balzano G; Di Carlo V; Brandes AA
Br J Cancer; 2006 Mar; 94(6):785-91. PubMed ID: 16508631
[TBL] [Abstract][Full Text] [Related]
18. Phase II study of gemcitabine, cisplatin, and infusional fluorouracil in advanced pancreatic cancer.
El-Rayes BF; Zalupski MM; Shields AF; Vaishampayan U; Heilbrun LK; Jain V; Adsay V; Day J; Philip PA
J Clin Oncol; 2003 Aug; 21(15):2920-5. PubMed ID: 12885810
[TBL] [Abstract][Full Text] [Related]
19. Concomitant administration of weekly oxaliplatin, fluorouracil continuous infusion, and radiotherapy after 2 months of gemcitabine and oxaliplatin induction in patients with locally advanced pancreatic cancer: a Groupe Coordinateur Multidisciplinaire en Oncologie phase II study.
Moureau-Zabotto L; Phélip JM; Afchain P; Mineur L; André T; Vendrely V; Lledo G; Dupuis O; Huguet F; Touboul E; Balosso J; Louvet C
J Clin Oncol; 2008 Mar; 26(7):1080-5. PubMed ID: 18309942
[TBL] [Abstract][Full Text] [Related]
20. Weekly gemcitabine and 24-hour infusional 5-fluorouracil in advanced pancreatic cancer: a phase I-II study.
Barone C; Cassano A; Corsi DC; Pozzo C; Longo R; Schinzari G; Quirino M; Battelli C; Basso M
Oncology; 2003; 64(2):139-45. PubMed ID: 12566911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
